Novel Digital Technologies and Biomarkers to Characterise Depression

Life Sciences, Clinical Trials, Drug Discovery & Development, Biomarkers,
  • Thursday, October 28, 2021 | 10am EDT (NA) / 3pm BST (UK) / 4pm CEST (EU-Central)
  • 60 min

The development of new treatment options for depression is hindered by a lack of objective, clinically relevant outcome measures that can adequately capture daily fluctuations in mood and cognition. Novel digital technologies offer the potential for more objective and precise symptom detection, but which best characterise depression?

In efforts to address this question, Novartis evaluated seven digital technologies spanning eye-tracking in the clinic to the daily use of a Cambridge Cognition mobile app at home. Recently published in Frontiers in Psychiatry, the researchers covered:

  • Which technologies are useful to distinguish between depressed and healthy subjects?
  • Can we build accurate classifiers (depressed vs. healthy) using parsimonious models with select digital biomarkers?
  • Can we explain between-subject variation in MADRS (and possibly predict individual MADRS scores) using digital biomarker data?

In this webinar, experts from Novartis and Cambridge Cognition will share lessons learned evaluating novel digital endpoints and building parsimonious models with high diagnostic accuracy and the potential to predict a standard clinical outcome for patients with depression.

Speakers

http://Dr.%20Francesca%20Cormack,%20Cambridge%20Cognition

Dr. Francesca Cormack, Director of Research & Innovation, Cambridge Cognition

Francesca Cormack is Director of Research and Innovation at Cambridge Cognition. She has worked to develop and validate novel cognitive testing methodology to support high-frequency near patient testing using wearable, mobile and voice technology, providing insights into cognitive health in a range of patient groups. Francesca obtained a Ph.D. in Dementia with Lewy Bodies at Newcastle University, followed by post-doctoral and academic positions at University College London and at the Medical Research Council in Cambridge. She is an Honorary Research Fellow at the University of Cambridge Department of Psychiatry and maintains academic collaborations focused on neurological disorders, ageing and psychiatry.

Message Presenter
http://Dr.%20Jelena%20Curcic,%20Novartis

Dr. Jelena Curcic, Senior Data Scientist, Novartis

Dr. Jelena Curcic is a Senior Data Scientist working at Novartis Institutes for Biomedical Research (NIBR) in Basel, Switzerland with the expertise in development, deployment and advanced analytics of digital biomarkers in Neuroscience. Her special topics of interest are cognition and neuropsychiatric symptoms in Alzheimer’s disease and mood disorders. She holds a Ph.D. in Biomedical Engineering from ETH in Zurich, Switzerland with a completely different topic of Magnetic Resonance Imaging in Gastrointestinal Tract.

Message Presenter
http://Dr.%20Kristin%20Hannesdottir,%20Novartis

Dr. Kristin Hannesdottir, Translational Medicine and Clinical Endpoint Expert, Novartis

Kristin is a translational medicine and clinical endpoint expert at Novartis Institutes for BioMedical Research. She holds a Ph.D. in Neuropsychology from King’s College University of London and more than 20 years of progressive experience in the field of neuroscience (12 years thereof in industry). Kristin has specialized in Alzheimer’s disease early clinical drug development and greatly appreciates the limitations we are faced with many of our current clinical endpoints and the need for innovation.

Message Presenter

Who Should Attend?

Professionals from Biotech, Pharmaceutical, CRO, Healthcare and Technology industries who work in:

  • Drug Development
  • Medical Affairs
  • Clinical Operations
  • Clinical Innovation
  • Patient Engagement
  • Virtual Trials
  • Digital Strategy
  • Digital Biomarkers

What You Will Learn

  • Which technologies are useful to distinguish between depressed and healthy subjects?
  • Can we build accurate classifiers (depressed vs. healthy) using parsimonious models with select digital biomarkers?
  • Can we explain between-subject variation in MADRS (and possibly predict individual MADRS scores) using digital biomarker data?

Xtalks Partner

Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

Media Partner

The original site for employees in the pharma, medical, diagnostic and related industries. Our hand-curated daily news feed and active message forums will keep you informed.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account